Extracellular vesicle-based anti-HOXB7 CD8+T cell-specific vaccination strengthens antitumor effects induced by vaccination against Her2/neu

Autor: Ferrantelli, Flavia, Manfredi, Francesco, Donnini, Micaela, Leone, Patrizia, Pugliese, Katherina, Olivetta, Eleonora, Giovannelli, Andrea, Di Virgilio, Antonio, Federico, Maurizio, Chiozzini, Chiara
Zdroj: Cancer Gene Therapy; 20240101, Issue: Preprints p1-8, 8p
Abstrakt: We previously developed an innovative strategy to induce CD8+T lymphocyte-immunity through in vivo engineering of extracellular vesicles (EVs). This approach relies on intramuscular injection of DNA expressing antigens of interest fused at a biologically-inactive HIV-1 Nef protein mutant (Nefmut). Nefmutis very efficiently incorporated into EVs, thus conveying large amounts of fusion proteins into EVs released by transfected cells. This platform proved successful against highly immunogenic tumor-specific antigens. Here, we tested whether antigen-specific CD8+T cell immune responses induced by engineered EVs can counteract the growth of tumors expressing two “self” tumor-associated antigens (TAAs): HOXB7 and Her2/neu. FVB/N mice were injected with DNA vectors expressing Nefmutfused to HOXB7 or Her2/neu, singly and in combination, before subcutaneous implantation of breast carcinoma cells co-expressing HOXB7 and Her2/neu. All mice immunized with the combination vaccine remained tumor-free, whereas groups vaccinated with single Nefmut-fused antigens were only partly protected, with stronger antitumor effects in Her2/neu-immunized mice. Double-vaccinated mice also controlled tumor growth upon a later tumor cell re-challenge. Importantly, co-vaccination also contained tumors in a therapeutic immunization setting. These results showed the efficacy of EV-based vaccination against two TAAs, and represent the first demonstration that HOXB7 may be targeted in multi-antigen immunotherapy strategies.
Databáze: Supplemental Index
Externí odkaz: